Quick Answer
Compass Therapeutics, Inc. reported Net Income of -$66.49 million for fiscal year 2025.
Compass Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$66.49M -34.7% |
-$49.38M -16.2% |
-$42.49M -8.3% |
-$39.23M +52.3% |
-$82.18M -219148.7% |
-$37.5K -4.0% |
| Total Assets | $219.59M +56.4% |
$140.40M -10.5% |
$156.88M -21.4% |
$199.65M +29.8% |
$153.76M +4105560.9% |
$3.7K -23.0% |
| Cash and Equivalents | $30.64M -29.5% |
$43.48M +79.5% |
$24.23M -30.7% |
$34.95M -75.8% |
$144.51M +3858751.8% |
$3.7K -23.0% |
| Long-Term Debt | — | — | — | — | $0.00 -100.0% |
$1.87M -79.9% |
| Stockholders Equity | $196.79M +57.1% |
$125.23M -15.7% |
$148.54M -18.2% |
$181.64M +29.7% |
$140.08M +129715.4% |
-$108.1K -53.1% |
| R&D Expense | — | — | — | — | — | $14.90M -33.6% |
| Operating Income | -$72.84M -28.6% |
-$56.62M -12.4% |
-$50.36M -20.9% |
-$41.66M +49.1% |
-$81.88M -254944.4% |
-$32.1K +2.0% |
| Shares Outstanding | 178.32M +29.4% |
137.82M +8.0% |
127.67M +1.1% |
126.30M +25.3% |
100.83M +1916.6% |
5.00M +0.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$14.26M | -36.0% | +28.3% |
| Total Assets | September 30, 2025 | $231.26M | +55.1% | +98.2% |
| Cash and Equivalents | September 30, 2025 | $46.21M | +138.2% | +102.2% |
| Long-Term Debt | September 30, 2021 | $0.00 | -100.0% | — |
| Stockholders Equity | September 30, 2025 | $209.61M | +51.5% | +124.9% |
| R&D Expense | March 31, 2021 | $4.70M | +31.7% | +28.2% |
| Operating Income | September 30, 2025 | -$15.82M | -29.2% | +24.9% |
| Shares Outstanding | September 30, 2025 | 177.57M | +29.1% | +28.4% |
- Compass Therapeutics, Inc. reported Net Income of -$66.49 million for fiscal year 2025.
- Compass Therapeutics, Inc. showed a decrease of -34.7% in Net Income compared to the prior fiscal year.
- Compass Therapeutics, Inc. reported Total Assets of $219.59 million for fiscal year 2025.
- Compass Therapeutics, Inc. showed an increase of +56.4% in Total Assets compared to the prior fiscal year.
- Compass Therapeutics, Inc. reported Cash and Equivalents of $30.64 million for fiscal year 2025.
- Compass Therapeutics, Inc. showed a decrease of -29.5% in Cash and Equivalents compared to the prior fiscal year.
- Compass Therapeutics, Inc. reported Long-Term Debt of $0.00 for fiscal year 2021.
- Compass Therapeutics, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Compass Therapeutics, Inc. reported Stockholders Equity of $196.79 million for fiscal year 2025.
- Compass Therapeutics, Inc. showed an increase of +57.1% in Stockholders Equity compared to the prior fiscal year.
- Compass Therapeutics, Inc. reported R&D Expense of $14.90 million for fiscal year 2020.
- Compass Therapeutics, Inc. showed a decrease of -33.6% in R&D Expense compared to the prior fiscal year.
- Compass Therapeutics, Inc. reported Operating Income of -$72.84 million for fiscal year 2025.
- Compass Therapeutics, Inc. showed a decrease of -28.6% in Operating Income compared to the prior fiscal year.
- Compass Therapeutics, Inc. reported Shares Outstanding of 178.32 million shares for fiscal year 2025.
- Compass Therapeutics, Inc. showed an increase of +29.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: